Related Experiment Video

Updated: Oct 12, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas?

T A Khwaja

    Cancer Treatment Reports
    |October 1, 1982
    PubMed

    Insights

    3-Deazaguanine (3-DG), a novel purine antagonist, demonstrates significant anticancer activity against various experimental solid tumors, including breast carcinoma models. Its efficacy against leukemias and other adenocarcinomas suggests potential for clinical trials.

    Area of Science:

    • Pharmacology and Toxicology
    • Experimental Oncology
    • Medicinal Chemistry

    Background:

    • 3-Deazaguanine (3-DG) is an emerging purine antagonist.
    • Anticancer drug development requires novel therapeutic agents.
    • Understanding the efficacy of novel compounds against diverse tumor models is crucial.

    Purpose of the Study:

    • To evaluate the anticancer activity of 3-Deazaguanine (3-DG) against a panel of experimental tumors.
    • To assess the potential of 3-DG as a therapeutic agent for solid tumors and leukemias.
    • To determine the suitability of 3-DG for further clinical investigation.

    Main Methods:

    • In vivo testing of 3-Deazaguanine (3-DG) against established experimental tumor models.
    • Evaluation of anti-tumor activity in slow- and rapid-growing solid tumors.
    • Assessment of efficacy against specific models including mammary adenocarcinomas and leukemias.

    Main Results:

    • 3-Deazaguanine (3-DG) exhibited significant activity against slow- and rapid-growing solid experimental tumors.
    • Demonstrated particular efficacy in models of human breast carcinomas (mammary adenocarcinomas 13762, R3230AC, C3H/16C).
    • Showed positive activity against leukemias (L1210, L1210/araC) and other adenocarcinomas (755, EMT-6).

    Conclusions:

    • 3-Deazaguanine (3-DG) possesses broad-spectrum anticancer activity in preclinical models.
    • Its demonstrated efficacy, especially against breast cancer models, warrants clinical evaluation.
    • 3-DG is progressing to clinical trials based on its promising antitumor profile.

    More Related Videos

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

    Published on: October 5, 2017

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

    Published on: June 9, 2023

    Related Concept Videos

    DNA Base Pairing02:27

    DNA Base Pairing

    Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
    Drugs that Stabilize Microtubules01:15

    Drugs that Stabilize Microtubules

    Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...